Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The Enfuse Solutions EPS (TTM) is -7.69. Enfuse Solutions reported sales of The Enfuse Solutions EPS (TTM) is -7.69. Enfuse Solutions reported sales of 312.82, net income of -85.20, and EPS of -9.85 ...

Enable Injections, maker of the enFuse wearable drug delivery system, inked a partnership deal with Incyte to join the companies' technologies in a bid to advance patient care in certain diseases. The ...

Incyte (NASDAQ:INCY) and Enable Injections, Inc. (“Enable”) today announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational, ...

Collaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies Under the terms of the agreement, ...

Under the terms of the agreement, Incyte will obtain a worldwide, exclusive license to use the enFuse technology with its mutCALR-targeted therapy (INCA033989) in essential thrombocythemia (ET) and ...

Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...

Windows 11 is available for download worldwide. Microsoft has released it as a free upgrade, which means you do not need to pay to upgrade your computer to Windows 11. It is available for free ...

Enable Injections, Inc. (Enable), a healthcare innovation company developing and manufacturing the enFuse on-body drug delivery system, announced that the Brazilian Health Regulatory Agency (Agencia ...

CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® on-body drug delivery system, announced ...